• Ei tuloksia

Atlas-informed computational processing pipeline for individual targeting of brain areas for therapeutic navigated transcranial magnetic stimulation

N/A
N/A
Info
Lataa
Protected

Academic year: 2022

Jaa "Atlas-informed computational processing pipeline for individual targeting of brain areas for therapeutic navigated transcranial magnetic stimulation"

Copied!
11
0
0

Kokoteksti

(1)

UEF//eRepository

DSpace https://erepo.uef.fi

Rinnakkaistallenteet Luonnontieteiden ja metsätieteiden tiedekunta

2021

Atlas-informed computational

processing pipeline for individual

targeting of brain areas for therapeutic

navigated transcranial magnetic stimulation

Reijonen, Jusa

Elsevier BV

Tieteelliset aikakauslehtiartikkelit

© 2021 International Federation of Clinical Neurophysiology CC BY http://creativecommons.org/licenses/by/4.0/

http://dx.doi.org/10.1016/j.clinph.2021.01.037

https://erepo.uef.fi/handle/123456789/25873

Downloaded from University of Eastern Finland's eRepository

(2)

Atlas-informed computational processing pipeline for individual

targeting of brain areas for therapeutic navigated transcranial magnetic stimulation

Jusa Reijonen

a,b,

, Mervi Könönen

c

, Pasi Tuunanen

a

, Sara Määttä

a

, Petro Julkunen

a,b

aDepartment of Clinical Neurophysiology, Kuopio University Hospital, Kuopio, Finland

bDepartment of Applied Physics, University of Eastern Finland, Kuopio, Finland

cDepartment of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland

a r t i c l e i n f o

Article history:

Accepted 29 January 2021 Available online 31 March 2021 Keywords:

Brain atlas

Dorsolateral prefrontal cortex Neuronavigation

Transcranial magnetic stimulation

h i g h l i g h t s

Anatomical identification of cortical target areas for navigated TMS is challenging.

Fitting the Brainnetome Atlas to the individual brain enabled consistent targeting.

Overlaying atlas information in the navigation view is a useful add-on for improving TMS targeting.

a b s t r a c t

Objective: Navigated transcranial magnetic stimulation (nTMS) is targeted at different cortical sites for diagnostic, therapeutic, and neuroscientific purposes. Correct identification of the cortical target areas is important for achieving desired effects, but it is challenging when no direct responses arise upon target area stimulation. We aimed at utilizing atlas-based marking of cortical areas for nTMS targeting to pre- sent a convenient, rater-independent method for overlaying the individual target sites with brain anat- omy.

Methods: We developed a pipeline, which fits a brain atlas to the individual brain and enables visualiza- tion of the target areas during the nTMS session. We applied the pipeline to our previous nTMS data, focusing on depression and schizophrenia patients. Furthermore, we included examples of Tourette syn- drome and tinnitus therapies, as well as neurosurgical and motor mappings.

Results: In depression and schizophrenia patients, the visually selected dorsolateral prefrontal cortex (DLPFC) targets were close to the border between atlas areas A9/46 and A8. In the other areas, the atlas-based areas were in agreement with the treatment targets.

Conclusions: The atlas-based target areas agreed well with the cortical targets selected by experts during the treatments.

Significance:Overlaying atlas information over the navigation view is a convenient and useful add-on for improving nTMS targeting.

Ó2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Transcranial magnetic stimulation (TMS) is used in repetitive TMS (rTMS) and theta-burst stimulation (TBS) modes for neuro- modulation therapy in a variety of conditions. Based on strong evidence from meta-analyses, European guidelines recommend applying high-frequency rTMS for beneficial effects on neuro- pathic pain and major depression (Lefaucheur et al. 2014, 2020). For these indications, the primary motor cortex (M1) con- tralateral to pain side and the left dorsolateral prefrontal cortex

https://doi.org/10.1016/j.clinph.2021.01.037

1388-2457/Ó2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Abbreviations:BA, Brodmann area; DLPFC, dorsolateral prefrontal cortex; DTI, diffusion tensor imaging; EEG, electroencephalogram; FDI, first dorsal interosseous;

fMRI, functional magnetic resonance imaging; MRI, magnetic resonance imaging;

M1, primary motor cortex; nTMS, navigated transcranial magnetic stimulation;

OCD, obsessive compulsive disorder; OFC, orbitofrontal cortex; rsfMRI, resting state functional magnetic resonance imaging; rTMS, repetitive transcranial magnetic stimulation; SMA, supplementary motor area; S2, secondary somatosensory cortex;

TBS, theta-burst stimulation.

Corresponding author at: Department of Clinical Neurophysiology, Kuopio University Hospital, POB 100, FI-70029 KYS, Kuopio, Finland.

E-mail address:jusa.reijonen@kuh.fi(J. Reijonen).

Clinical Neurophysiology 132 (2021) 1612–1621

Contents lists available atScienceDirect

Clinical Neurophysiology

j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / c l i n p h

(3)

(DLPFC) should be targeted, respectively (O’Reardon et al. 2007;

George et al. 2010; Hosomi et al. 2013). The updated guidelines also recommend applying low-frequency rTMS of contralesional M1 at the post-acute stage after stroke (Lefaucheur et al. 2020).

In addition, the guidelines suggest probable efficacy for the use of low-frequency rTMS of the right DLPFC in depression and high-frequency rTMS of ipsilesional M1 at the post-acute stage after stroke (Lefaucheur et al. 2014, 2020). Additional treatment targets with possible positive effects include the left auditory cor- tex in tinnitus and the supplementary motor area (SMA) in obses- sive compulsive disorder (OCD) (Lefaucheur et al. 2014; Singh et al. 2019).

Treatment target localization is crucial for treatment outcome;

therefore, utilization of neuronavigation in TMS therapy has been proven to provide more appropriate and successful targeting than non-navigated approaches (Lefaucheur et al. 2007; Fitzgerald et al.

2009b; Herbsman et al. 2009; Ahdab et al. 2010). When targeting therapy to motor areas, navigated TMS (nTMS) mapping can be uti- lized for treatment target selection (Vitikainen et al. 2009;

Julkunen 2014). In non-motor areas, such as the DLPFC, targets based on external landmarks have mainly been used when neuron- avigation is not available (Lefaucheur et al. 2014). This ‘‘standard”

approach locates the DLPFC target 5 cm anteriorly to the M1 (George et al. 1995), often failing to reach the correct cortical region (Herwig et al. 2001). Other proposed methods for more accurate DLPFC targeting include electroencephalogram (EEG) electrode positions F3 and F5 (for left DLPFC) (Rusjan et al.

2010), visual estimation based on structural magnetic resonance images (MRIs) using anatomical landmarks (Mylius et al. 2013) or indirect clearly identifiable anatomical features (Pommier et al. 2017), and connectivity-based target selection (Fox et al.

2012a, 2013). The use of external or anatomical landmarks for set- ting the treatment target tends to cause variability in target selec- tion (Ahdab et al. 2010), which also increases the between-study variability in the reported therapeutic effects of TMS. Therefore, a clear, individualized method independent from rater-specific interpretation would be preferable.

Treatments for various conditions have widely extended the applicability of nTMS. However, treatment target identification is often done by clinicians who are not necessarily accustomed with MRI in their clinical work. The typical anatomical treatment targets are in the DLPFC, M1, or the auditory cortex, which are often referred to with their specific associated Brodmann areas (BAs).

Conventional DLPFC targets are located at the medioposterior part of BA46, lateral to BA9 and anterior to BA8 (Fitzgerald et al. 2009b;

Fox et al. 2012a). M1 is located in BA4, and the auditory cortex is approximately in BA41 and BA42. Optional targets for pain therapy are in the right secondary somatosensory cortex (S2) (Lindholm et al. 2015). For OCD, targets are in SMA and the orbitofrontal cor- tex (OFC) (Singh et al. 2019).

The Brodmann atlas contains invaluable information on struc- tural–functional relationships based on cortical cytoarchitecture (Amunts and Zilles 2015). However, this classical cortical map was constructed by analyzing a single hemisphere, neglecting the inter-individual variability. It does not provide accurate informa- tion on the borders of the cortical areas. Furthermore, it represents only local features, ignoring the long-range connections of the brain, which are crucial in determining the functions of a cortical area (Passingham et al. 2002). Incorporating these connections into brain mapping reveals a more heterogenous cortical architecture, providing refined atlases with fine-grained parcellations. The Brainnetome Atlas (Fan et al. 2016), which we utilize, has been constructed by parcellating the cortical anatomy based on struc- tural connectivity information from 40 brains. It uses the BAs in nomenclature, since most clinicians and researchers are familiar with this labeling approach (Fig. 1).

The aim of the present study is to provide a demonstration of a pipeline, which utilizes the Brainnetome Atlas (Fan et al. 2016) with FreeSurfer (Fischl 2012) to enable identification of crucial target areas over structural MRI volumes of the patients. This allows target selection during the TMS treatment session by uti- lizing individually fitted atlas information. We note that the applied atlas provides areas based on anatomical connectivity;

therefore, the resulting areas differ from the conventional BAs.

We demonstrate the pipeline retrospectively in various rTMS therapy patients and healthy subjects, focusing primarily on the DLPFC. The pipeline presented in this study will provide an approach to more efficient and stable treatment target selection for rTMS and TBS therapies.

2. Methods

2.1. Subjects and imaging

We analyzed 22 subjects (mean age: 35.5 years, range: 17–

67 years, 13 male, 9 female). A summary of the subjects and treat- ment target areas is presented inTable 1. Prior to nTMS, structural three-dimensional T1-weighted MRI volumes were acquired with a 3-T scanner (Philips Achieva 3.0TX, Philips, Eindhoven, The Nether- lands). Two different commercial nTMS systems were used: eXimia 3.2 and NBS 4.2 (Nexstim Plc, Helsinki, Finland).

2.2. Pipeline

The applied pipeline used a three-dimensional, T1-weighted MRI and some user-defined parameters as inputs and automati- cally performed multiple processing steps to produce a final corti- cal volume that can be overlaid with the original MRI in the nTMS system (Fig. 2). The processing steps utilized several functions of the FreeSurfer suite (Fischl 2012), together with the connectivity- based parcellation data provided by the Brainnetome Atlas (Fan et al. 2016).

First, the MRI DICOM image stack was converted into a volume file (NIfTI format). This volume was segmented and parcellated with FreeSurfer reconstruction methods to obtain a gyral-based cortical parcellation (Desikan et al. 2006). This initial parcellation was divided into sub-regions by the Brainnetome Atlas, which was mapped to the processed image. After this step, a registration matrix was created, which performed a mapping from the atlas space (the standard MNI space) to the individual MRI coordinates.

By utilizing the atlas, the regions of interest were identified based on atlas label indices representing the parcellated sub-regions.

Finally, the selected labels (see Appendix A for the specific atlas indices) were converted into an image volume, where the volume between the white matter surface and pia mater was painted (Fig. 3). By utilizing the previously formed registration matrix, the final image volume was transformed into the individual MRI space, which enabled visualizing the target area on individual cor- tical anatomy in the nTMS session.

The pipeline was implemented in a single Linux shell script (Appendix C). We used FreeSurfer version 6.0.0 in Ubuntu 16.04, installed in VirtualBox version 5.2.8 (Oracle Co, San Francisco, CA) under Windows 7 and 10 (Microsoft Co, Redmond, WA) oper- ating systems. The time required for running the pipeline was about 12 h.

2.3. Comparison with alternative approaches

The pipeline was applied retrospectively to all subjects. In the DLPFC, the neuroanatomical method proposed by Mylius et al.

(2013)was applied to obtain a reference target, and the shortest

(4)

distance of this target to the edges of the neighboring atlas-based areas (A9/46, A8, and A9) was calculated. Thus, the reference target in the DLPFC did not represent the actual treatment target applied for the depression and schizophrenia patients. We aimed at com- paring the applicability of the neuroanatomical reference method and the atlas pipeline in these patients, since both of these condi- tions may alter the cortical neuroanatomy (Schmaal et al. 2017;

van Erp et al. 2018).

In the other cortical treatment areas (SMA and auditory cortex), we validated the pipeline visually by overlaying the treatment tar- get selected by the clinician during the treatment session with the atlas-based target area produced by the pipeline. The neurosurgical language mappings (stimulation sites associated with responses) were also overlaid with the atlas-based Wernicke’s area. In these mappings, the patients performed object-naming tasks, and rTMS was used to impair task performance (Krieg et al. 2017). The coil was moved randomly over the perisylvian cortex with the orienta- tion approximately perpendicular to the nearest sulcus.

Finally, the agreement between the mapped motor cortical tar- get, and the target area provided by the pipeline was also visual- ized in case fashion. The reference target in the motor cortex was the hotspot of the first dorsal interosseous (FDI) muscle, which was located accurately in an nTMS motor mapping protocol. This protocol applied a slightly suprathreshold stimulation inducing around 1-mV motor-evoked potentials (MEPs) in the target mus- cle. The stimulation was started from the anatomically identified

‘‘hand knob” (Yousry et al. 1997) and extended to the neighboring sites until no MEPs were elicited. The stimulation site repeatedly producing the highest MEPs was identified as the FDI hotspot.

3. Results

The applied pipeline functioned fully in all subjects. In the depression (S1–S10, Fig. 4) and schizophrenia (S11–S13,Fig. 4) patients, the visually determined DLPFC targets were located in the atlas area A9/46 (62% of the targets) or in A8 (38% of the tar- gets). Table 2 shows the shortest distances of these targets to the edges of the neighboring areas A9/46, A8, and A9, separately for both hemispheres. For the targets in A8, the distance to A9/46 was 7 ± 3 mm (both hemispheres). For the targets in A9/46, the distance to A8 was 5 ± 3 mm. For all the DLPFC tar- gets, the distance to A9 was 21 ± 5 mm. The targets were thus located close to the border between A9/46 and A8, lateral to A9 (Fig. 4).

In the Tourette syndrome patients (S14–S15,Fig. B1in Appen- dix B), the applied therapy targets were located in the target area (SMA) produced by the pipeline. In the tinnitus patient (S16, Fig. B1 in Appendix B), the therapy target was located in the atlas-based auditory cortex. In the neurosurgical mapping patients (S17–S18,Fig. B2in Appendix B), most of the stimulation sites associated with responses were in agreement with the obtained target areas. Based on qualitative, visual estimation, these target areas (auditory cortex and Wernicke’s area) were consistent with their common neuroanatomical locations. The motor cortex was also effectively visualized by the pipeline for the motor mapping subjects (S19–S22, Fig. B3 in Appendix B).

This target area corresponded well with the hotspot of the FDI muscle (Fig. B3in Appendix B): all hotspots were located in the target area.

Fig. 1.Various target areas identified in a single subject on both hemispheres based on the Brainnetome Atlas (Fan et al. 2016). M1, primary motor cortex; SMA, supplementary motor area; S2, secondary somatosensory cortex.

Table 1

Summary of subjects and nTMS target areas. DLPFC, dorsolateral prefrontal cortex; M1, primary motor cortex; rTMS, repetitive transcranial magnetic stimulation; SMA, supplementary motor area.

Indication/purpose System Target Number of subjects Reference method

Depression, rTMS therapy NBS 4.2 DLPFC 10 Mylius et al. (2013)

Schizophrenia, rTMS therapy eXimia 3.2 DLPFC 3 Mylius et al. (2013)

Tourette, rTMS therapy eXimia 3.2 SMA 2 Treatment target selected by a clinician

Tinnitus, rTMS therapy eXimia 3.2 Auditory cortex 1 Treatment target selected by a clinician

Neurosurgical mapping NBS 4.2 Wernicke’s area 2 Language mapping

Research, motor mapping NBS 4.2 M1 4 Motor mapping

J. Reijonen, M. Könönen, P. Tuunanen et al. Clinical Neurophysiology 132 (2021) 1612–1621

1614

(5)

4. Discussion

In the current study, we demonstrated how a brain atlas can be applied for identifying individualized treatment target areas for rTMS and TBS therapies. The resulting target areas agreed well with the reference targets in the DLPFC, SMA, auditory cortex, Wer- nicke’s area, and M1.

In the DLPFC, the targets determined with the neuroanatomical method (Mylius et al. 2013) were located in A9/46 or A8 of the Brainnetome Atlas (Fan et al. 2016), close to the border between these two areas and lateral to A9 (Fig. 4). The original method (Mylius et al. 2013) targets the junction between anatomical areas BA9 and BA46 in the Talairach atlas, which has different area def- initions than the Brainnetome Atlas; this junction is likely a part of A9/46 in the Brainnetome Atlas as implied by the best agreement with the method ofMylius et al. (2013)(Table 2). This conventional method uses the precentral sulcus and the olfactory sulcus as anatomical landmarks for specifying the target location in the pos- terior–anterior axis, which may cause variability in this direction (Pommier et al. 2017). For locating the target in the medial–lateral direction, the neuroanatomical method requires identifying the middle frontal gyrus. In the Brainnetome Atlas, the middle frontal gyrus near the neuroanatomical target corresponds to areas A9/46 and A8vl (Fan et al. 2016). By using the proposed pipeline, locating the center of the border between A9/46 and A8vl potentially pro- vides an individual, rater-independent method for targeting the DLPFC. This approach targets the DLPFC in a more consistent man- ner and is less prone to human errors than the conventional method based on anatomical landmarks.

The DLPFC is a relatively large area, which is often assumed to consist of the conventional areas BA46, BA9, and area A9/46 intro- duced byPetrides and Pandya (1999). There is no consensus on the most effective target area in context of medication-resistant depression; previous studies have suggested targeting BA46 (Fox et al. 2012a), BA9 (Luber et al. 2017), and also their junction (Fitzgerald et al. 2009a; Herbsman et al. 2009) to enhance the ther- apeutic effects. Conventionally, these areas are derived from the Talairach atlas, which can lead to erroneous designations due to high inter-individual anatomical variability that still remains after transformation to a reference brain (Uylings et al. 2005). The accu- rate specification of individual BAs requires microstructural analy- sis of the post-mortem brain; however, probabilistic brain atlases enable macrostructural estimation based on in vivo MRI. Alterna- tive connectivity-based methods apply individual resting state functional MRI (rsfMRI) (Fox et al. 2012b; Cole et al. 2020).

The Brainnetome Atlas provides a fine-grained, connectivity- based parcellation, which enables targeting based on anatomical Fig. 2. Pipeline and the steps of image processing, all (black boxes) implemented in

a script for running in series. MRI, magnetic resonance image; nTMS, navigated transcranial magnetic stimulation.

Fig. 3.Automatically painted cortical volume representing the Brainnetome Atlas area A9/46 (blue area) between white matter surface (yellow) and pia mater (red) on the left hemisphere.

(6)

and functional connectivity. This will potentially increase the treatment efficacy, assuming that the selected targets are integral parts of the dysfunctioning networks involved in the pathophysiol- ogy of depression (Fox et al. 2012a; Luber et al. 2017). This group- based targeting of functionally relevant areas is a significant improvement on the ‘‘standard” approaches, providing spatially confined target areas when individual functional MRI (fMRI) data is not available. It is also more accessible than the conventional neuroanatomical methods, since it does not require profound knowledge on cortical anatomy.

It is unclear whether straightforward anatomical targeting is sufficient for effective nTMS treatments, since connectivity-based targeting has been shown to produce promising results (Fox et al.

2012a). More research is required to yield the relevant parameters

for identifying the optimal treatment target; in addition to the con- nectivity of the treatment target with structures involved in the pathophysiology of depression, metabolic characteristics might provide useful parameters (Paillère Martinot et al. 2010).

As stated earlier, the areas of the Brainnetome Atlas are not con- sistent with the original BAs; however, the nomenclature is based on these areas, with the refinements of area 9/46 provided byPetrides and Pandya (1999). Our pipeline is straighforward to apply with any brain atlas, as the repertoire of atlases continues to evolve (Dickie et al. 2017); it also involves the Desikan-Killiany atlas (Desikan et al. 2006), which is a coarse anatomical atlas based on gyral geom- etry.Petrides (2019)presented a more detailed anatomical atlas based on the cortical morphology of the MNI brain. It provides a ser- ies of coronal sections, where the gyri, sulci, and the likely locations Fig. 4.Visually determined treatment targets (black dots) and atlas-based areas A9/46 (red), A9 (yellow), and A8 (blue) of individual depression (S1–S10) and schizophrenia (S11–S13) patients. These targets were identified retrospectively by utilizing the method ofMylius et al. (2013).

J. Reijonen, M. Könönen, P. Tuunanen et al. Clinical Neurophysiology 132 (2021) 1612–1621

1616

(7)

of the cortical areas are identified. To compare these anatomically defined areas with the Brainnetome Atlas areas, we performed a coarse comparison of their locations in the posterior–anterior axis (Appendix D). Based on this comparison, the average locations of these areas seem to match relatively well, while some differences exist in their extents in the posterior–anterior direction.

Considering the other target areas obtained in the current study, the SMA and auditory cortex were visualized for the Tour- ette syndrome and tinnitus patients, respectively (Fig. B1 in Appendix B). Previous studies on these indications and OCD have mainly identified the treatment targets by utilizing the interna- tional 10–20 EEG system (Lefaucheur et al. 2014). In contrast to this approach, our atlas-based method considers the underlying gyral anatomy, enabling more accurate targeting when combined with neuronavigation. During neurosurgical mapping near the Wernicke’s area, the visualized areas provide additional guidance (Fig. B2in Appendix B). In the motor cortex, A4 exhibits large spa- tial extent (Fig. B3in Appendix B), and motor mapping is the most reliable method for identifying a muscle-specific treatment target.

However, visualizing the motor cortex during nTMS could provide additional guidance for inexperienced users.

The proposed pipeline has limitations, the most important being the possible designation errors when registering a group- based atlas to the individual brain MRI volume. Because of these errors, the target areas may not be reliably identified for individu- als with significantly deviating cortical morphologies. Especially, when applying an atlas based on healthy subjects to individual patients, this reliability could be further reduced due to disease- related functional plasticity. The second limitation is the time required to run the pipeline: in practice, the MRI and the pipeline need to be performed the day before the nTMS procedure. Further optimization of the FreeSurfer implementation could reduce the time required for running the pipeline. More clinical studies are needed to investigate whether the more accurate targeting improves the effects of rTMS and TBS therapies on the various indi- cations. However, the potential of the demonstrated method is not limited to the identification of treatment targets; brain atlases can

be used, for example, as seed points for diffusion tensor imaging (DTI) tractography, identifying individualized cortical targets with most probable connections to subcortical targets.

5. Conclusion

We demonstrate the application of the Brainnetome Atlas in identifying various treatment target areas. These areas include the DLPFC for the treatments of depression and schizophrenia, SMA for OCD and Tourette, and auditory cortex for tinnitus to be used with rTMS and TBS. Additional benefits may be in the identi- fication of treatment targets for pain therapy and in guiding the mapping of language and motor areas. Finally, the individual target areas can be valuable in scientific research when targeting non- motor areas, such as the SMA for TMS–EEG.

Declaration of Competing Interest

Petro Julkunen has a patent with Nexstim Plc, manufacturer of nTMS systems. The rest of the authors declare no competing interests.

Acknowledgements

Jusa Reijonen and Petro Julkunen acknowledge the Research Committee of the Kuopio University Hospital Catchment Area for the State Research Funding (projects 5041763 and 5041771, Kuo- pio, Finland); the Academy of Finland (grant number 322423);

and Cancer Society of Finland (Helsinki, Finland). Jusa Reijonen was also funded by the Vilho, Yrjö and Kalle Väisälä Foundation of the Finnish Academy of Science and Letters (Helsinki, Finland);

and Päivikki and Sakari Sohlberg Foundation (Helsinki, Finland).

Appendix A Table A1 Table 2

Distances of the visually determined dorsolateral prefrontal cortex (DLPFC) targets to the edges of the atlas-based areas A9/46, A8, and A9. The targets were determined visually by applying the method proposed byMylius et al. (2013). This method aims to target the junction between anatomical areas BA9 and BA46 in the Talairach atlas.

Subject Left target Right target

Brainnetome Atlas area targeted by the method of Mylius et al.

Distance to A9/46 (mm)

Distance to A8 (mm)

Distance to A9 (mm)

Brainnetome Atlas area targeted by the method of Mylius et al.

Distance to A9/46 (mm)

Distance to A8 (mm)

Distance to A9 (mm)

1 A9/46 - 10 18 A9/46 - 2 17

2 A9/46 - 2 17 A9/46 - 8 10

3 A9/46 - 5 21 A9/46 - 3 27

4 A9/46 - 6 23 A9/46 - 4 15

5 A8 5 - 29 A8 6 - 20

6 A9/46 - 10 21 A8 8 - 22

7 A9/46 - 5 27 A8 11 - 21

8 A9/46 - 4 30 A9/46 - 3 18

9 A8 7 - 25 A9/46 - 2 17

10 A9/46 - 8 22 A8 9 - 20

11 A9/46 - 7 23 A9/46 - 4 16

12 A8 5 - 25 A8 9 - 23

13 A8 2 - 18 A8 6 - 20

Mean 5 6 23 8 4 19

Std 2 3 4 2 2 4

Table A1

Atlas indices. DLPFC, dorsolateral prefrontal cortex; M1, primary motor cortex; SMA, supplementary motor area.

Anatomical area Indications Atlas indices

DLPFC (A9/46) Depression Schizophrenia A9/46d_L, A9/46v_L (left hemisphere) and A9/46d_R, A9/46v_R (right hemisphere)

SMA (medial part of A6) Tourette A6m_L, A6dl_L, and A6m_R, A6dl_R

Auditory cortex (A41/42) Tinnitus A41/42_L, A22c_L, A22r_L, TE1.0_TE1.2_L and A41/42_R, A22c_R, A22r_R, TE1.0_TE1.2_R Wernicke (A22 and A40) Neurosurgical mapping A22c_L, A40c_L, A40rv_L, A40rd_L and A22c_R, A40c_R, A40rv_R, A40rd_R

M1 (A4), precentral gyrus Research, motor mapping A4hf_L, A4ul_L, A4t_L, A4tl_L, A4ll_L and A4hf_R, A4ul_R, A4t_R, A4tl_R, A4ll_R

(8)

Fig. B1.Target area A6 (green) of individual Tourette syndrome patients (S14 and S15) and auditory cortex (A41/42 and A22, pink) of the tinnitus patient (S16) based on atlas information. The black dots indicate the treatment targets selected by a clinician.

Fig. B2.Wernicke’s areas (A22, red; A40, blue) of individual neurosurgical mapping patients based on atlas information. The black dots indicate the cortical sites associated with speech responses.

J. Reijonen, M. Könönen, P. Tuunanen et al. Clinical Neurophysiology 132 (2021) 1612–1621

1618

(9)

Appendix B Figs. B1-B3

Appendix C. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.clinph.2021.01.037.

Appendix D Tables D1 and D2

Fig. B3.Motor hotspots and atlas-based target area A4 (purple) of individual motor mapping subjects. The black dots indicate the motor hotspots of the first dorsal interosseous (FDI) muscle.

Table D1

Y coordinates (posterior–anterior) of Average MNI Brain (Petrides, 2019) and Brainnetome Atlas (Fan et al. 2016) areas.

Average MNI Brain area

Y coordinates

Brainnetome Atlas area

Y coordinate (left/right hemisphere)

8B 31–35 A8m 15/16

8B 31–35 A8dl 24/26

8A 15–23 A8vl 23/27

9 51 A9m 36/38

9 51 A9l 49/48

9/46d 31–51 A9/46d 43/37

9/46v 31–35 A9/46v 41/44

(10)

References

Ahdab R, Ayache SS, Brugières P, Goujon C, Lefaucheur J-P. Comparison of

‘‘standard” and ‘‘navigated” procedures of TMS coil positioning over motor, premotor and prefrontal targets in patients with chronic pain and depression.

Neurophysiol Clin Neurophysiol 2010;40(1):27–36. https://doi.org/10.1016/j.

neucli.2010.01.001.

Amunts K, Zilles K. Architectonic mapping of the human brain beyond Brodmann.

Neuron 2015;88(6):1086–107.https://doi.org/10.1016/j.neuron.2015.12.001.

Cole EJ, Stimpson KH, Bentzley BS, Gulser M, Cherian K, Tischler C, Nejad R, Pankow H, Choi E, Aaron H, Espil FM, Pannu J, Xiao X, Duvio D, Solvason HB, Hawkins J, Guerra A, Jo B, Raj KS, Phillips AL, Barmak F, Bishop JH, Coetzee JP, DeBattista C, Keller J, Schatzberg AF, Sudheimer KD, Williams NR. Stanford accelerated intelligent neuromodulation therapy for treatment-resistant depression. Am J Psychiatry 2020;177(8):716–26. https://doi.org/10.1176/appi.

ajp.2019.19070720.

Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage 2006;31(3):968–80.https://doi.org/10.1016/j.

neuroimage.2006.01.021.

Dickie DA, Shenkin SD, Anblagan D, Lee J, Blesa Cabez M, Rodriguez D, et al. Whole brain magnetic resonance image atlases: a systematic review of existing atlases and caveats for use in population imaging. Front Neuroinform 2017;11.https://

doi.org/10.1371/journal.pone.0127939.

Fan L, Li H, Zhuo J, Zhang Yu, Wang J, Chen L, Yang Z, Chu C, Xie S, Laird AR, Fox PT, Eickhoff SB, Yu C, Jiang T. The human Brainnetome Atlas: a new brain atlas based on connectional architecture. Cereb Cortex 2016;26(8):3508–26.https://

doi.org/10.1093/cercor/bhw157.

Fischl B. FreeSurfer. NeuroImage 2012;62(2):774–81. https://doi.org/10.1016/j.

neuroimage.2012.01.021.

Fitzgerald PB, Hoy K, McQueen S, Maller JJ, Herring S, Segrave R, Bailey M, Been G, Kulkarni J, Daskalakis ZJ. A randomized trial of rTMS targeted with MRI based neuro-navigation in treatment-resistant depression.

Neuropsychopharmacology 2009a;34(5):1255–62. https://doi.org/10.1038/

npp.2008.233.

Fitzgerald PB, Maller JJ, Hoy KE, Thomson R, Daskalakis ZJ. Exploring the optimal site for the localization of dorsolateral prefrontal cortex in brain stimulation experiments. Brain Stimul 2009b;2(4):234–7. https://doi.org/10.1016/j.

brs.2009.03.002.

Fox MD, Buckner RL, White MP, Greicius MD, Pascual-Leone A. Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biol Psychiatry 2012a;72 (7):595–603.https://doi.org/10.1016/j.biopsych.2012.04.028.

Fox MD, Halko MA, Eldaief MC, Pascual-Leone A. Measuring and manipulating brain connectivity with resting state functional connectivity magnetic resonance imaging (fcMRI) and transcranial magnetic stimulation (TMS). NeuroImage 2012b;62(4):2232–43.https://doi.org/10.1016/j.neuroimage.2012.03.035.

Fox MD, Liu H, Pascual-Leone A. Identification of reproducible individualized targets for treatment of depression with TMS based on intrinsic connectivity.

NeuroImage 2013;66:151–60. https://doi.org/10.1016/j.

neuroimage.2012.10.082.

George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE, Schwartz T, Sackeim HA. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 2010;67(5):507. https://doi.org/10.1001/

archgenpsychiatry.2010.46.

George MS, Wassermann EM, Williams WA, Callahan A, Ketter TA, Basser P, Hallett M, Post RM. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport 1995;6(14):1853–6.https://doi.org/10.1097/

00001756-199510020-00008.

Herbsman T, Avery D, Ramsey D, Holtzheimer P, Wadjik C, Hardaway F, Haynor D, George MS, Nahas Z. More lateral and anterior prefrontal coil location is associated with better repetitive transcranial magnetic stimulation antidepressant response. Biol Psychiatry 2009;66(5):509–15.https://doi.org/

10.1016/j.biopsych.2009.04.034.

Herwig U, Padberg F, Unger J, Spitzer M, Schönfeldt-Lecuona C. Transcranial magnetic stimulation in therapy studies: examination of the reliability of

‘‘standard” coil positioning by neuronavigation. Biol Psychiatry 2001;50 (1):58–61.https://doi.org/10.1016/S0006-3223(01)01153-2.

Hosomi K, Shimokawa T, Ikoma K, Nakamura Y, Sugiyama K, Ugawa Y, Uozumi T, Yamamoto T, Saitoh Y. Daily repetitive transcranial magnetic stimulation of primary motor cortex for neuropathic pain: a randomized, multicenter, double- blind, crossover, sham-controlled trial. Pain 2013;154(7):1065–72.https://doi.

org/10.1016/j.pain.2013.03.016.

Julkunen P. Methods for estimating cortical motor representation size and location in navigated transcranial magnetic stimulation. J Neurosci Methods 2014;232:125–33.https://doi.org/10.1016/j.jneumeth.2014.05.020.

Krieg SM, Lioumis P, Mäkelä JP, Wilenius J, Karhu J, Hannula H, Savolainen P, Lucas CW, Seidel K, Laakso A, Islam M, Vaalto S, Lehtinen H, Vitikainen A-M, Tarapore PE, Picht T. Protocol for motor and language mapping by navigated TMS in patients and healthy volunteers; workshop report. Acta Neurochir (Wien) 2017;159(7):1187–95.https://doi.org/10.1007/s00701-017-3187-z.

Lefaucheur J-P, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, Filipovic´ SR, Grefkes C, Hasan A, Hummel FC, Jääskeläinen SK, Langguth B, Leocani L, Londero A, Nardone R, Nguyen J-P, Nyffeler T, Oliveira-Maia AJ, Oliviero A, Padberg F, Palm U, Paulus W, Poulet E, Quartarone A, Rachid F, Rektorová I, Rossi S, Sahlsten H, Schecklmann M, Szekely D, Ziemann U.

Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014–2018). Clin Neurophysiol 2020;131(2):474–528.https://doi.org/10.1016/j.clinph.2019.11.002.

Lefaucheur J-P, André-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH, Cantello RM, Cincotta M, de Carvalho M, De Ridder D, Devanne H, Di Lazzaro V, Filipovic´ SR, Hummel FC, Jääskeläinen SK, Kimiskidis VK, Koch G, Langguth B, Nyffeler T, Oliviero A, Padberg F, Poulet E, Rossi S, Rossini PM, Rothwell JC, Schönfeldt-Lecuona C, Siebner HR, Slotema CW, Stagg CJ, Valls-Sole J, Ziemann U, Paulus W, Garcia-Larrea L. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 2014;125(11):2150–206.https://doi.org/10.1016/j.clinph.2014.05.021.

Lefaucheur JP, Brugières P, Ménard-Lefaucheur I, Wendling S, Pommier M, Bellivier F. The value of navigation-guided rTMS for the treatment of depression: an illustrative case. Neurophysiol Clin 2007;37(4):265–71. https://doi.org/

10.1016/j.neucli.2007.07.003.

Lindholm P, Lamusuo S, Taiminen T, Pesonen U, Lahti A, Virtanen A, Forssell H, Hietala J, Hagelberg N, Pertovaara A, Parkkola R, Jääskeläinen S. Right secondary somatosensory cortex-a promising novel target for the treatment of drug- resistant neuropathic orofacial pain with repetitive transcranial magnetic stimulation. Pain 2015;156(7):1276–83. https://doi.org/10.1097/

j.pain.0000000000000175.

Luber BM, Davis S, Bernhardt E, Neacsiu A, Kwapil L, Lisanby SH, Strauman TJ.

Reprint of ‘‘Using neuroimaging to individualize TMS treatment for depression:

toward a new paradigm for imaging-guided intervention”. NeuroImage 2017;151:65–71.https://doi.org/10.1016/j.neuroimage.2017.03.049.

Mylius V, Ayache SS, Ahdab R, Farhat WH, Zouari HG, Belke M, Brugières P, Wehrmann E, Krakow K, Timmesfeld N, Schmidt S, Oertel WH, Knake S, Lefaucheur JP. Definition of DLPFC and M1 according to anatomical landmarks for navigated brain stimulation: inter-rater reliability, accuracy, and influence of gender and age. NeuroImage 2013;78:224–32. https://doi.org/10.1016/j.

neuroimage.2013.03.061.

O’Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA.

Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007;62(11):1208–16.https://doi.org/10.1016/j.biopsych.2007.01.018.

Paillère Martinot M-L, Galinowski A, Ringuenet D, Gallarda T, Lefaucheur J-P, Bellivier F, Picq C, Bruguière P, Mangin J-F, Rivière D, Willer J-C, Falissard B, Leboyer M, Olié J-P, Artiges E, Martinot J-L. Influence of prefrontal target region on the efficacy of repetitive transcranial magnetic stimulation in patients with medication-resistant depression: A [18F]-fluorodeoxyglucose PET and MRI study. Int J Neuropsychopharmacol 2010;13(01):45.https://doi.org/10.1017/

S146114570900008X.

Passingham RE, Stephan KE, Kötter R. The anatomical basis of functional localization in the cortex. Nat Rev Neurosci 2002;3(8):606–16. https://doi.org/10.1038/

nrn893.

Petrides M. Atlas of the morphology of the human cerebral cortex on the average MNI brain. Elsevier; 2019.

Petrides M, Pandya DN. Dorsolateral prefrontal cortex: comparative cytoarchitectonic analysis in the human and the macaque brain and corticocortical connection patterns. Eur J Neurosci 1999;11:1011–36.https://

doi.org/10.1046/j.1460-9568.2001.02090.x.

Pommier B, Vassal F, Boutet C, Jeannin S, Peyron R, Faillenot I. Easy methods to make the neuronavigated targeting of DLPFC accurate and routinely accessible for rTMS. Neurophysiol Clin 2017;47(1):35–46. https://doi.org/10.1016/j.

neucli.2017.01.007.

Rusjan PM, Barr MS, Farzan F, Arenovich T, Maller JJ, Fitzgerald PB, et al. Optimal transcranial magnetic stimulation coil placement for targeting the dorsolateral prefrontal cortex using novel magnetic resonance image-guided neuronavigation. Hum Brain Mapp 2010;31(11):1643–52. https://doi.org/

10.1002/hbm.20964.

Schmaal L, Hibar DP, Sämann PG, Hall GB, Baune BT, Jahanshad N, Cheung JW, van Erp TGM, Bos D, Ikram MA, Vernooij MW, Niessen WJ, Tiemeier H, Hofman A, Wittfeld K, Grabe HJ, Janowitz D, Bülow R, Selonke M, Völzke H, Grotegerd D, Table D2

Y coordinate ranges (posterior–anterior) of Brainnetome Atlas areas for the 10 depression patients.

Area Range, left Middle point, left Range, right Middle point, right

A8m 1–30 16 2–33 18

A8dl 4–39 22 7–39 23

A8vl 7–37 22 11–38 25

A9m 16–56 36 17–55 36

A9l 25–68 46 28–68 48

A9/

46d

28–56 42 15–52 33

A9/46v 23–57 40 19–58 39

J. Reijonen, M. Könönen, P. Tuunanen et al. Clinical Neurophysiology 132 (2021) 1612–1621

1620

(11)

Dannlowski A, Arolt V, Opel N, Heindel W, Kugel H, Hoehn D, Czisch M, Couvy- Duchesne B, Rentería ME, Strike LT, Wright MJ, Mills NT, de Zubicaray GI, McMahon KL, Medland SE, Martin NG, Gillespie NA, Goya-Maldonado R, Gruber O, Krämer B, Hatton SN, Lagopoulos J, Hickie IB, Frodl T, Carballedo A, Frey EM, van Velzen LS, Penninx BWJH, van Tol M-J, van der Wee NJ, Davey CG, Harrison BJ, Mwangi B, Cao B, Soares JC, Veer IM, Walter H, Schoepf D, Zurowski B, Konrad C, Schramm E, Normann C, Schnell K, Sacchet MD, Gotlib IH, MacQueen GM, Godlewska BR, Nickson T, McIntosh AM, Papmeyer M, Whalley HC, Hall J, Sussmann JE, Li M, Walter M, Aftanas L, Brack I, Bokhan NA, Thompson PM, Veltman DJ. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. Mol Psychiatry 2017;22(6):900–9.

https://doi.org/10.1038/mp.2016.60.

Singh S, Kumar S, Gupta A, Verma R, Kumar N. Effectiveness and predictors of response to 1-Hz repetitive transcranial magnetic stimulation in patients with obsessive-compulsive disorder. J ECT 2019;35(1):61–6.https://doi.org/10.1097/

YCT.0000000000000530.

Uylings HBM, Rajkowska G, Sanz-Arigita E, Amunts K, Zilles K. Consequences of large interindividual variability for human brain atlases: converging macroscopical imaging and microscopical neuroanatomy. Anat Embryol (Berl) 2005;210(5–6):423–31.https://doi.org/10.1007/s00429-005-0042-4.

van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, Pearlson GD, Yao N, Fukunaga M, Hashimoto R, Okada N, Yamamori H, Bustillo JR, Clark VP, Agartz I, Mueller BA, Cahn W, de Zwarte SMC, Hulshoff Pol HE, Kahn RS, Ophoff RA, van Haren NEM, Andreassen OA, Dale AM, Doan NT, Gurholt TP, Hartberg CB, Haukvik UK, Jørgensen KN, Lagerberg TV, Melle I, Westlye LT, Gruber O, Kraemer B, Richter A, Zilles D, Calhoun VD, Crespo-Facorro B, Roiz-Santiañez R, Tordesillas-Gutiérrez D, Loughland C, Carr VJ, Catts S, Cropley VL, Fullerton JM, Green MJ, Henskens FA, Jablensky A, Lenroot RK, Mowry BJ, Michie PT, Pantelis C, Quidé Y, Schall U, Scott RJ, Cairns MJ, Seal M, Tooney PA, Rasser PE, Cooper G, Shannon Weickert C, Weickert TW, Morris DW, Hong E, Kochunov P, Beard LM,

Gur F, Gur RC, Satterthwaite TD, Wolf DH, Belger A, Brown GG, Ford JM, Macciardi F, Mathalon DH, O’Leary DS, Potkin SG, Preda A, Voyvodic J, Lim KO, McEwen S, Yang F, Tan Y, Tan S, Wang Z, Fan F, Chen J, Xiang H, Tang S, Guo H, Wan P, Wei D, Bockholt HJ, Ehrlich S, Wolthusen RPF, King MD, Shoemaker JM, Sponheim SR, De Haan L, Koenders L, Machielsen MW, van Amelsvoort T, Veltman DJ, Assogna F, Banaj N, de Rossi P, Iorio M, Piras F, Spalletta G, McKenna PJ, Pomarol-Clotet E, Salvador R, Corvin A, Donohoe G, Kelly S, Whelan CD, Dickie EW, Rotenberg D, Voineskos AN, Ciufolini S, Radua J, Dazzan P, Murray R, Reis Marques T, Simmons A, Borgwardt S, Egloff L, Harrisberger F, Riecher- Rössler A, Smieskova R, Alpert KI, Wang L, Jönsson EG, Koops S, Sommer IEC, Bertolino A, Bonvino A, Di Giorgio A, Neilson E, Mayer AR, Stephen JM, Kwon JS, Yun J-Y, Cannon DM, McDonald C, Lebedeva I, Tomyshev AS, Akhadov T, Kaleda V, Fatouros-Bergman H, Flyckt L, Busatto GF, Rosa PGP, Serpa MH, Zanetti MV, Hoschl C, Skoch A, Spaniel F, Tomecek D, Hagenaars SP, McIntosh AM, Whalley HC, Lawrie SM, Knöchel C, Oertel-Knöchel V, Stäblein M, Howells FM, Stein DJ, Temmingh HS, Uhlmann A, Lopez-Jaramillo C, Dima D, McMahon A, Faskowitz JI, Gutman BA, Jahanshad N, Thompson PM, Turner JA, Farde L, Flyckt L, Engberg G, Erhardt S, Fatouros-Bergman H, Cervenka S, Schwieler L, Piehl F, Agartz I, Collste K, Victorsson P, Malmqvist A, Hedberg M, Orhan F. Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) consortium. Biol Psychiatry 2018;84(9):644–54. https://doi.org/10.1016/j.

biopsych.2018.04.023.

Vitikainen A-M, Lioumis P, Paetau R, Salli E, Komssi S, Metsähonkala L, Paetau A, Kicˇic´ D, Blomstedt G, Valanne L, Mäkelä JP, Gaily E. Combined use of non- invasive techniques for improved functional localization for a selected group of epilepsy surgery candidates. NeuroImage 2009;45(2):342–8. https://doi.org/

10.1016/j.neuroimage.2008.12.026.

Yousry TA, Schmid UD, Alkadhi H, Schmidt D, Peraud A, Buettner A, et al.

Localization of the motor hand area to a knob on the precentral gyrus. A new landmark Brain 1997;120(1):141–57.https://doi.org/10.1093/brain/120.1.141.

Viittaukset

LIITTYVÄT TIEDOSTOT

2009, "Comparison of navigated and non-navigated transcranial magnetic stimulation for motor cortex mapping, motor threshold and motor evoked potentials.

Abstract: Cortical motor mapping in pre-surgical applications can be performed using motor evoked potential (MEP) amplitudes evoked with neuronavigated transcranial

We investigated whether and how different interneuronal circuits contribute to such resonance by using transcranial magnetic stimulation (TMS) during transcranial alternating

In this study, we examined the motor cortex structure and function using navigated transcranial magnetic stimulation (nTMS) and voxel-based morphometry (VBM) and correlated

Methods: Navigated transcranial magnetic stimulation (TMS) was used to compare motor thresholds (MTs), motor evoked potentials (MEPs), short-interval intracortical inhibition (SICI)

Abstract: Cortical motor mapping in pre-surgical applications can be performed using motor evoked potential (MEP) amplitudes evoked with neuronavigated transcranial

The present clinical applications of TMS were taken from the review of Kobayashi and Pascual-Leone (2003). In TMS–EEG experiments, the condition of any selected cortical area and

The present data are consistent with and strengthen this line of evidence, demonstrating that rightOFA plays a causal role in encoding of non-face stimuli and that such involvement